Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) technology to develop transformative vaccines and therapeutics. With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for infectious diseases, cancers, and rare conditions. 

Shares of Moderna have significantly underperformed the broader market over the past year. The stock has declined 39% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 35.9%. In 2024 alone, MRNA stock is down 57%, while the SPX is up 25.8% on a YTD basis.